JavaScript seems to be disabled in your browser.
You must have JavaScript enabled in your browser to utilize the functionality of this website.

Pharmaceuticals & Biotechnology Market Research Reports

To refine your search by industry, market, geographic region, country or price, use Advanced Search or contact Client Services for assistance.

36
37
38
39
40

Report Title

Published

Price

Optic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$2,000.00
Proliferative Vitreoretinopathy (PVR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$2,000.00
Bronchopulmonary Dysplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$2,000.00
Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$2,000.00
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
Cell Division Protein FtsZ (ftsz) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
Dystrophin (DMD) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

April 29, 2022

$3,500.00
Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

April 29, 2022

$2,500.00
Brain Hemorrhage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

April 29, 2022

$2,000.00
Ornithine Decarboxylase (ODC or ODC1 or EC 4.1.1.17) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

April 29, 2022

$2,500.00
Interstitial Lung Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

April 29, 2022

$2,000.00
Progressive Familial Intrahepatic Cholestasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

April 29, 2022

$2,000.00
Ectonucleoside Triphosphate Diphosphohydrolase 1 (NTPDase 1 or Ecto ATP Diphosphohydrolase 1 or Ecto Apyrase or Lymphoid Cell Activation Antigen or CD39 or ENTPD1 or EC 3.6.1.5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Mole

April 29, 2022

$2,500.00
Transferrin Receptor Protein 1 (T9 or p90 or CD71 or TFRC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

April 29, 2022

$2,500.00
Angiotensin Converting Enzyme 2 (ACE Related Carboxypeptidase or Metalloprotease MPROT15 or Angiotensin Converting Enzyme Homolog or ACE2 or EC 3.4.17.23) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Playe

April 29, 2022

$2,500.00
Myeloproliferative Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

April 29, 2022

$2,500.00
Platelet Derived Growth Factor Receptor (PDGFR or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

April 29, 2022

$2,500.00
Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1) Drug

April 29, 2022

$3,500.00
Charcot-Marie-Tooth Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

April 28, 2022

$2,000.00

36
37
38
39
40